Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 2Unknown 1Terminated 1Approved for marketing 1

Sponsor Class

OTHER 5

Study Type

Interventional 3Observational 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 6Lymphoid 6Other hematologic neoplasm 5Other 2Genitourinary 1

Conditions

Osteosarcoma 3Renal Insufficiency 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Water Intoxication 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Acute Kidney Injury 1

Interventions

Cyclophosphamide 678Cytarabine 576fludarabine 410fludarabine phosphate 387venetoclax 310Methotrexate 297Rituximab 283Azacitidine 264Busulfan 248Whole-Body Irradiation 220Etoposide 215Filgrastim 214Peripheral Blood Stem Cell Transplantation 211Mycophenolic Acid 206Tacrolimus 196Dexamethasone 191Granulocyte Colony-Stimulating Factor 182Vincristine 173Melphalan 173Decitabine 163Cyclosporine 146Daunorubicin 139Antilymphocyte Serum 137Idarubicin 134Imatinib Mesylate 127Lenalidomide 116Doxorubicin 109Radiotherapy 108Stem Cell Transplantation 107Clofarabine 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × glucarpidase × Other hematologic neoplasm × Clear all
NCT05899751 2024-05-10

Retrospective Registry Study of Patients With Cancer Treated With High-dose Methotrexate

BTG International Inc.

Unknown
1,000 enrolled
GenitourinaryOther hematologic neoplasmSarcoma

Osteosarcoma, Water Intoxication, Hematologic Neoplasms, Acute Kidney Injury, Drug-Related Side Effects and Adverse Reactions

NCT00634504 2022-06-06

LVPK

BTG International Inc.

Phase 1 Completed
20 enrolled 9 charts
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Osteosarcoma, Renal Insufficiency

NCT01305655 2018-09-28

NOPHOCPG2

Nordic Society for Pediatric Hematology and Oncology

Phase 3 Completed
47 enrolled 5 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

NCT00424645 2012-12-06

Voraxaze for Delayed Methotrexate Clearance

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 2 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡